The development of novel agents such as HER2-targeting monoclonal antibodies, antibody–drug conjugates (ADC), and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors has dramatically improved the survival outcome of hormone receptor (HR)-positive breast cancer and HER2-positive breast cancer [13,14]. This evidence concerns the gene ERBB2 and breast cancer.